Human RCTPubMed ID: 36356234·2022

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Garvey WT, Batterham RL, Bhatt DL, et al.

Nature Medicine, 2022 · n = 304

Key finding

Semaglutide 2.4mg maintained 15.2% weight loss at 2 years, demonstrating durable efficacy with continued treatment.

Summary

Two-year study confirming durability of semaglutide weight loss. Maintained 15.2% mean weight reduction at 104 weeks vs 2.6% for placebo.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

JAMA Cardiology · 2022 · Human Pilot